Ilya Yakavets
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ilya Yakavets has a total of 270 co-authors. Here are the top co-authors by number of shared publications:
- Lina Bezdetnaya
Research Department, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France
15 shared publications - Henri-Pierre Lassalle
Université de Lorraine
9 shared publications - Eugenia Kumacheva
Department of Chemistry, University of Toronto, Toronto, Ontario M5S 3H6, Canada
6 shared publications Henri-Pierre Lassalle
Université de Lorraine and CNRS, CRAN, UMR 7039, F-54000 Nancy, France
6 shared publicationsVladimir Zorin
Laboratory of Biophysics and Biotechnology, Belarusian State University, Minsk, Belarus
6 shared publications- Vladimir Zorin
Laboratory of Biophysics and Biotechnology, Belarusian State University, 4 Nezavisimosti Avenue, 220030 Minsk, Belarus
6 shared publications
Latest Publications
- 9 November 2026
- Published by Springer Nature in Nature Reviews Bioengineering
- p. 1-3
Open-source hardware for biomanufacturing
- 9 November 2026
- Published by Springer Nature in Nature Reviews Bioengineering
- p. 1-3
Open-source hardware for biomanufacturing
- 3 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Cyclodextrin-based photoactive liposomal nanoparticles for tumor targeting
Ciblage tumoral par des nanoparticules photoactivable basée sur des complexes de cyclodextrines encapsulées dans des liposomes: La thérapie photodynamique (PDT) est un traitement alternatif du cancer plus ciblé et moins invasif que les modalités traditionnelles. La Temoporfine (mTHPC, nom sous forme médicamenteuse : Foscan®), est l'un des PS les plus puissants cliniquement approuvés. Cependant, sa faible solubilité en milieu aqueux a provoqué plusieurs complications lors de son administration. La présente étude vise à mettre au point des nanoparticules constituées d’une molécule anticancéreuse couplée à la cyclodextrine intégré dans un liposome (drug-in-cyclodextrin-in-liposome, DCL) en couplant deux systèmes d'administration indépendants : les complexes d'inclusion cyclodextrine-mTHPC et les vésicules liposomales pour améliorer le transport et la pénétration de la mTHPC dans le tissu cible. La formation de complexes d'inclusion entre les cyclodextrines et la mTHPC a été étudiée en détail. Sur la base de ces données, des mTHPC-DCL à simple et double charge ont été préparées, optimisées et caractérisées. Il a été démontré que les mTHPC-DCL sont stables et que presque tous les mTHPC-DCL sont liés à β-CDs dans la lumière aqueuse interne des liposomes. L'influence des DCLs sur l'accumulation, la distribution et l'efficacité photodynamique de la mTHPC a été étudiée dans des modèles cellulaire en monocouche et sphéroïde multicellulaires 3D d’adénocarcinome de pharynx humain (HT29). En utilisant des sphéroïdes, nous avons démontré que le DCL à base de triméthyl-β-CD fournissait une accumulation homogène de la mTHPC dans tout le volume des sphéroïdes tumoraux, suggérant ainsi une distribution optimale de la mTHPC.
- 3 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Cyclodextrin-based photoactive liposomal nanoparticles for tumor targeting
Ciblage tumoral par des nanoparticules photoactivable basée sur des complexes de cyclodextrines encapsulées dans des liposomes: La thérapie photodynamique (PDT) est un traitement alternatif du cancer plus ciblé et moins invasif que les modalités traditionnelles. La Temoporfine (mTHPC, nom sous forme médicamenteuse : Foscan®), est l'un des PS les plus puissants cliniquement approuvés. Cependant, sa faible solubilité en milieu aqueux a provoqué plusieurs complications lors de son administration. La présente étude vise à mettre au point des nanoparticules constituées d’une molécule anticancéreuse couplée à la cyclodextrine intégré dans un liposome (drug-in-cyclodextrin-in-liposome, DCL) en couplant deux systèmes d'administration indépendants : les complexes d'inclusion cyclodextrine-mTHPC et les vésicules liposomales pour améliorer le transport et la pénétration de la mTHPC dans le tissu cible. La formation de complexes d'inclusion entre les cyclodextrines et la mTHPC a été étudiée en détail. Sur la base de ces données, des mTHPC-DCL à simple et double charge ont été préparées, optimisées et caractérisées. Il a été démontré que les mTHPC-DCL sont stables et que presque tous les mTHPC-DCL sont liés à β-CDs dans la lumière aqueuse interne des liposomes. L'influence des DCLs sur l'accumulation, la distribution et l'efficacité photodynamique de la mTHPC a été étudiée dans des modèles cellulaire en monocouche et sphéroïde multicellulaires 3D d’adénocarcinome de pharynx humain (HT29). En utilisant des sphéroïdes, nous avons démontré que le DCL à base de triméthyl-β-CD fournissait une accumulation homogène de la mTHPC dans tout le volume des sphéroïdes tumoraux, suggérant ainsi une distribution optimale de la mTHPC.
- Open Access
- 24 February 2026
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 232, 115835
From conventional screening to self-driving discovery: Organ-on-Chip platforms as engines for AI-guided nanomedicine
- 24 February 2026
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 232, 115835
Open AccessFrom conventional screening to self-driving discovery: Organ-on-Chip platforms as engines for AI-guided nanomedicine
- Open Access
- 19 November 2025
- Published by Royal Society of Chemistry (RSC) in Digital Discovery
- Vol. 5 (1) , 93-97
Commit: Digital pipette: open hardware for liquid transfer in self-driving laboratories
We present an updated version of the digital pipette, an economical 3D-printed device for accurate liquid transfers by robotic arms. The new version supports disposable tip replacement to reduce contamination while maintaining high accuracy.
- 19 November 2025
- Published by Royal Society of Chemistry (RSC) in Digital Discovery
- Vol. 5 (1) , 93-97
Open AccessCommit: Digital pipette: open hardware for liquid transfer in self-driving laboratories
We present an updated version of the digital pipette, an economical 3D-printed device for accurate liquid transfers by robotic arms. The new version supports disposable tip replacement to reduce contamination while maintaining high accuracy.
- Open Access
- 1 August 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (31) , eadt1851
Machine learning-assisted exploration of multidrug-drug administration regimens for organoid arrays
Combination therapies enhance the therapeutic effect of cancer treatment; however, identifying effective interdependent doses, durations, and sequences of multidrug administration regimens is a time- and labor-intensive task. Here, we integrated machine learning, automation, and large microfluidic arrays of cancer spheroids or patient-derived organoids formed in a tissue-mimetic hydrogel to achieve notable acceleration of the discovery of effective multidrug administration regimens. For the clinically approved drug combination, we found a sequential administration regimen leading to a substantial reduction in the total drug dose, in comparison with concurrent drug supply, both at comparable drug efficacy. For the drugs that are currently under clinical development, we found a synergistic effect of concurrently administered drugs and showed that the synergy diminishes for the sequential drug supply. The developed strategy holds promise for the discovery of effective combination therapies for advanced cancer treatment, including personalized chemotherapies.
- 1 August 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (31) , eadt1851
Open AccessMachine learning-assisted exploration of multidrug-drug administration regimens for organoid arrays
Combination therapies enhance the therapeutic effect of cancer treatment; however, identifying effective interdependent doses, durations, and sequences of multidrug administration regimens is a time- and labor-intensive task. Here, we integrated machine learning, automation, and large microfluidic arrays of cancer spheroids or patient-derived organoids formed in a tissue-mimetic hydrogel to achieve notable acceleration of the discovery of effective multidrug administration regimens. For the clinically approved drug combination, we found a sequential administration regimen leading to a substantial reduction in the total drug dose, in comparison with concurrent drug supply, both at comparable drug efficacy. For the drugs that are currently under clinical development, we found a synergistic effect of concurrently administered drugs and showed that the synergy diminishes for the sequential drug supply. The developed strategy holds promise for the discovery of effective combination therapies for advanced cancer treatment, including personalized chemotherapies.
- 26 June 2025
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 25 (16) , 4038-4047
Spheroid-based skin-on-a-chip platform for the evaluation of the toxicity of small molecules and nanoparticles
Exposure of human skin to chemical agents may lead to skin sensitization, irritation, and corrosion. Time-efficient toxicity screening is currently achieved using in vitro skin-on-a-chip models; however, these either lack a multilayer structure characteristic of the skin, or require long fabrication time. Here, we report the development and proof-of-concept application of the microfluidic spheroid-based skin-on-a-chip platform utilizing gravity-driven flow and large arrays of multilayer skin spheroids (MSSs). The MSSs containing human dermal fibroblasts in the core and keratinocytes in the shell replicated the dermal and epidermal layers of skin, respectively. Within 3 days, the toxicity of five distinct small molecules was characterized by measuring their IC50 values, which enabled the differentiation of non-irritant chemical agents from the irritant ones and correlated with their in vivo scores for skin irritation. Toxicity screening was extended to nanoparticles, including carbon dots, liposomes, and insecticide-loaded liposomes. This MSS-based skin-on-a-chip microfluidic platform for the safety evaluation of small molecules and nanoparticles has diverse applications in the skincare, pharmaceutical, and agriculture fields.
- 26 June 2025
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 25 (16) , 4038-4047
Spheroid-based skin-on-a-chip platform for the evaluation of the toxicity of small molecules and nanoparticles
Exposure of human skin to chemical agents may lead to skin sensitization, irritation, and corrosion. Time-efficient toxicity screening is currently achieved using in vitro skin-on-a-chip models; however, these either lack a multilayer structure characteristic of the skin, or require long fabrication time. Here, we report the development and proof-of-concept application of the microfluidic spheroid-based skin-on-a-chip platform utilizing gravity-driven flow and large arrays of multilayer skin spheroids (MSSs). The MSSs containing human dermal fibroblasts in the core and keratinocytes in the shell replicated the dermal and epidermal layers of skin, respectively. Within 3 days, the toxicity of five distinct small molecules was characterized by measuring their IC50 values, which enabled the differentiation of non-irritant chemical agents from the irritant ones and correlated with their in vivo scores for skin irritation. Toxicity screening was extended to nanoparticles, including carbon dots, liposomes, and insecticide-loaded liposomes. This MSS-based skin-on-a-chip microfluidic platform for the safety evaluation of small molecules and nanoparticles has diverse applications in the skincare, pharmaceutical, and agriculture fields.
- Open Access
- 22 June 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Bayesian Optimization Hackathon for Chemistry and Materials
The Acceleration Consortium and Merck KGaA hosted a 2-day virtual hackathon on March 27- 28, 2024, bringing together scientists to explore, collaborate, and innovate in the field of Bayesian optimization for the physical sciences. Participants were encouraged to select or develop Bayesian optimization algorithms, apply them to benchmarking tasks, design new benchmarks, create instructional tutorials, and describe real-world applications. With over 100 participants across 69 academic, industry, and government organizations located in 59 cities, 19 countries, and 4 continents, this was a global event. The outputs from this event, including developed algorithms, benchmarks, and tutorials, will serve as valuable resources for the research community, in addition to the new skills learned and connections formed. Released projects and general information are available at https://ac-bo-hackathon.github.io/ and other locations linked from individual project pages. This event demonstrates the potential of community-driven research efforts to accelerate advances in Bayesian optimization in chemistry and materials science.
- 22 June 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessBayesian Optimization Hackathon for Chemistry and Materials
The Acceleration Consortium and Merck KGaA hosted a 2-day virtual hackathon on March 27- 28, 2024, bringing together scientists to explore, collaborate, and innovate in the field of Bayesian optimization for the physical sciences. Participants were encouraged to select or develop Bayesian optimization algorithms, apply them to benchmarking tasks, design new benchmarks, create instructional tutorials, and describe real-world applications. With over 100 participants across 69 academic, industry, and government organizations located in 59 cities, 19 countries, and 4 continents, this was a global event. The outputs from this event, including developed algorithms, benchmarks, and tutorials, will serve as valuable resources for the research community, in addition to the new skills learned and connections formed. Released projects and general information are available at https://ac-bo-hackathon.github.io/ and other locations linked from individual project pages. This event demonstrates the potential of community-driven research efforts to accelerate advances in Bayesian optimization in chemistry and materials science.
- 13 November 2024
- Published by American Chemical Society (ACS) in The Journal of Physical Chemistry B
- Vol. 128 (47) , 11625-11633
Efficient Delivering of a Photodynamic Therapy Drug into Cellular Membranes Rationalized by Molecular Dynamics
Photodynamic therapy (PDT) represents a most attractive therapeutic strategy to reduce side-effects of chemotherapy and improve the global quality of life of patients. Yet, many PDT drugs suffer from poor bioavailability and cellular intake, and thus, drug-delivering strategies are mandatory. In this article, we rationalize the behavior of a temoporfin-based PDT drug, commercialized under the name of Foscan, complexed by two β-cyclodextrin units, acting as drug carriers, in the presence of a lipid bilayer. Our all-atom simulations have unequivocally shown the internalization of the drug-delivering complex and suggest its possible spontaneous dissociation in the lipid bilayer core. The factors favoring penetration and dissociation have also been analyzed, together with membrane perturbation due to the interaction with the drug carrier complex. Our results confirm the suitability of this encapsulation strategy for PDT and rationalize the experimental results concerning its efficacy.
- 13 November 2024
- Published by American Chemical Society (ACS) in The Journal of Physical Chemistry B
- Vol. 128 (47) , 11625-11633
Efficient Delivering of a Photodynamic Therapy Drug into Cellular Membranes Rationalized by Molecular Dynamics
Photodynamic therapy (PDT) represents a most attractive therapeutic strategy to reduce side-effects of chemotherapy and improve the global quality of life of patients. Yet, many PDT drugs suffer from poor bioavailability and cellular intake, and thus, drug-delivering strategies are mandatory. In this article, we rationalize the behavior of a temoporfin-based PDT drug, commercialized under the name of Foscan, complexed by two β-cyclodextrin units, acting as drug carriers, in the presence of a lipid bilayer. Our all-atom simulations have unequivocally shown the internalization of the drug-delivering complex and suggest its possible spontaneous dissociation in the lipid bilayer core. The factors favoring penetration and dissociation have also been analyzed, together with membrane perturbation due to the interaction with the drug carrier complex. Our results confirm the suitability of this encapsulation strategy for PDT and rationalize the experimental results concerning its efficacy.
- Open Access
- 14 September 2024
- Published by Wiley in Advanced Materials
- Vol. 36 (44) , e2410547
Microfluidic Platform for Generating and Releasing Patient‐Derived Cancer Organoids with Diverse Shapes: Insight into Shape‐Dependent Tumor Growth
Multicellular spheroids and patient‐derived organoids find many applications in fundamental research, drug discovery, and regenerative medicine. Advances in the understanding and recapitulation of organ functionality and disease development require the generation of complex organoid models, including organoids with diverse morphologies. Microfluidics‐based cell culture platforms enable time‐efficient confined organoid generation. However, the ability to form organoids with different shapes with a subsequent transfer from microfluidic devices to unconstrained environments for studies of morphology‐dependent organoid growth is yet to be demonstrated. Here, a microfluidic platform is introduced that enables high‐fidelity formation and addressable release of breast cancer organoids with diverse shapes. Using this platform, the impact of organoid morphology on their growth in unconstrained biomimetic hydrogel is explored. It is shown that proliferative cancer cells tend to localize in high positive curvature organoid regions, causing their faster growth, while the overall growth pattern of organoids with diverse shapes tends to reduce interfacial tension at the organoid‐hydrogel interface. In addition to the formation of organoids with diverse morphologies, this platform can be integrated into multi‐tissue micro‐physiological systems.
- 14 September 2024
- Published by Wiley in Advanced Materials
- Vol. 36 (44) , e2410547
Open AccessMicrofluidic Platform for Generating and Releasing Patient‐Derived Cancer Organoids with Diverse Shapes: Insight into Shape‐Dependent Tumor Growth
Multicellular spheroids and patient‐derived organoids find many applications in fundamental research, drug discovery, and regenerative medicine. Advances in the understanding and recapitulation of organ functionality and disease development require the generation of complex organoid models, including organoids with diverse morphologies. Microfluidics‐based cell culture platforms enable time‐efficient confined organoid generation. However, the ability to form organoids with different shapes with a subsequent transfer from microfluidic devices to unconstrained environments for studies of morphology‐dependent organoid growth is yet to be demonstrated. Here, a microfluidic platform is introduced that enables high‐fidelity formation and addressable release of breast cancer organoids with diverse shapes. Using this platform, the impact of organoid morphology on their growth in unconstrained biomimetic hydrogel is explored. It is shown that proliferative cancer cells tend to localize in high positive curvature organoid regions, causing their faster growth, while the overall growth pattern of organoids with diverse shapes tends to reduce interfacial tension at the organoid‐hydrogel interface. In addition to the formation of organoids with diverse morphologies, this platform can be integrated into multi‐tissue micro‐physiological systems.
- 15 February 2024
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 16 (8) , 9690-9701
A Microfluidic Platform for Evaluating the Internalization of Liposome Drug Carriers in Tumor Spheroids
The development of in vitro models recapitulating nanoparticle transport under physiological flow conditions is of great importance for predicting the efficacy of nanoparticle drug carriers. Liposomes are extensively used for drug delivery owing to their biocompatibility and biodegradability and the ability to carry both hydrophilic and hydrophobic compounds. Here, we used a library of liposomes with various dimensions and a microfluidic platform comprising a large array of uniformly sized breast cancer spheroids to explore size-dependent liposome internalization and retention in the spheroids under close-to-physiological interstitial conditions. Such a platform showed promising applications in the preclinical screening of small molecule drugs; however, the capability to deliver nanoparticles in the spheroid interior under close-to-physiological flow conditions was not explored. For the liposomes with diameters in the range of 45-200 nm, we show experimentally and by simulations that in comparison with liposome delivery solely by diffusion, flow significantly enhances liposome internalization in the microgels and mitigates the size-dependent spheroid penetration by the liposomes. The utility of the microfluidic platform was validated by evaluating the efficacy of clinically approved doxorubicin-loaded liposomes (Doxil), which exhibited superior retention in the spheroids under flow conditions, in comparison with free doxorubicin. This MF platform can serve as an in vitro model for screening the efficacy of drugs encapsulated in liposomes and find applications for screening other types of nanoparticle carriers for vaccine delivery, diagnostics, and skincare.
- 15 February 2024
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 16 (8) , 9690-9701
A Microfluidic Platform for Evaluating the Internalization of Liposome Drug Carriers in Tumor Spheroids
The development of in vitro models recapitulating nanoparticle transport under physiological flow conditions is of great importance for predicting the efficacy of nanoparticle drug carriers. Liposomes are extensively used for drug delivery owing to their biocompatibility and biodegradability and the ability to carry both hydrophilic and hydrophobic compounds. Here, we used a library of liposomes with various dimensions and a microfluidic platform comprising a large array of uniformly sized breast cancer spheroids to explore size-dependent liposome internalization and retention in the spheroids under close-to-physiological interstitial conditions. Such a platform showed promising applications in the preclinical screening of small molecule drugs; however, the capability to deliver nanoparticles in the spheroid interior under close-to-physiological flow conditions was not explored. For the liposomes with diameters in the range of 45-200 nm, we show experimentally and by simulations that in comparison with liposome delivery solely by diffusion, flow significantly enhances liposome internalization in the microgels and mitigates the size-dependent spheroid penetration by the liposomes. The utility of the microfluidic platform was validated by evaluating the efficacy of clinically approved doxorubicin-loaded liposomes (Doxil), which exhibited superior retention in the spheroids under flow conditions, in comparison with free doxorubicin. This MF platform can serve as an in vitro model for screening the efficacy of drugs encapsulated in liposomes and find applications for screening other types of nanoparticle carriers for vaccine delivery, diagnostics, and skincare.